Back to search

Article

Targetable <i>ERBB2</i> mutation status is an independent marker of adverse prognosis in estrogen receptor positive, <i>ERBB2</i> non-amplified primary lobular breast carcinoma: a retrospective <i>in silico</i> analysis of public datasets

2020-01-27

Abstract excerpt

<h4>Background</h4> Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tractable mechanism underlying enhanced human epidermal growth factor 2 (HER2) activity. We tested the hypothesis that therapeutically targetable ERBB2/3 mutations in primary ILC of the brea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c9c950e5-1fad-5383-a996-a5de1573b539
DOI
10.1101/2020.01.24.20018622
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targetable <i>ERBB2</i> mutation status is an independent marker of adverse prognosis in estrogen receptor positive, <i>ERBB2</i> non-amplified primary lobular breast carcinoma: a retrospective <i>in silico</i> analysis of public datasetsDOI 10.1101/2020.01.24.20018622
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.Semantic proximity
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity
Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breastSemantic proximity
Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis.Semantic proximity
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.Semantic proximity
Comparative Analysis of Clinical and Molecular Characteristics in Invasive Ductal Carcinoma of the BreastSemantic proximity
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Semantic proximity
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Semantic proximity
IKZF3 amplification frequently occurs in HER2 positive breast cancer and is a potential therapeutic targetSemantic proximity
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.Semantic proximity
Select gene mutations associated with survival outcomes in ER-positive ERBB2-negative early-stage invasive breast cancer: A single-institutional tissue bank study.Semantic proximity
Breast cancer mutations HER2 <sup>V777L</sup> and PIK3CA <sup>H1047R</sup> activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistanceSemantic proximity
Select a neighboring publication to make it the new centre.